BioSpace News Archive

Drug Development

Mindbio Therapeutics First Batch of MB22001 has Been Manufactured and is Ready for Use in World First Phase 2 Take at Home Psychedelic Clinical Trials

MindBio Therapeutics Corp. is excited to announce it has received its first batch of MB22001 ready for take-home use in Phase 2 psychedelic microdosing clinical trials.

August 18, 2023
·
5 min read
Drug Development

Merck Announces WELIREG® (belzutifan) Phase 3 LITESPARK-005 Trial Met Primary Endpoint of Progression-Free Survival in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma

Merck, known as MSD outside of the United States and Canada, announced topline results from LITESPARK-005, the first positive Phase 3 trial investigating WELIREG, Merck’s oral hypoxia-inducible factor-2 alpha inhibitor.

August 18, 2023
·
12 min read
Drug Development

Akeso Announced First Patient Dosed in Phase 3 Trial of Ivonescimab versus Tislelizumab for First-line Treatment of Squamous NSCLC

Akeso Inc. (“Akeso”, 9926. HK) announced today that the first patient has been dosed in a head-to-head phase III trial of ivonescimab, a potential first-in-class investigational PD-1/VEGF bi-specific antibody discovered by Akeso.

August 18, 2023
·
5 min read
Business

Satio partners with BARDA DRIVe to develop a novel patch-based ebolavirus diagnostic

Satio is pleased to announce a contract awarded by the Biomedical Advanced Research and Development Authority ( BARDA ), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services to develop a novel, single-use, rapid ebolavirus diagnostic.

August 18, 2023
·
2 min read
BioCapital

Aditxt, Inc. (NASDAQ: ADTX) Provides Shareholder Update and Planned Strategy for Achieving Commercial Scale

Aditxt®, Inc. is pleased to provide an important update regarding its innovation programs and strategic M&A initiatives.

August 18, 2023
·
9 min read
Drug Development

Amber Ophthalmics Announces First Patient Enrolled in NEXPEDE-1, a Phase 2/3 Clinical Trial Evaluating Nexagon for the Treatment of Persistent Corneal Epithelial Defects

Amber Ophthalmics, Inc. (Amber) , a privately held, clinical stage biopharmaceutical company, announced today that Dr. Mark S. Gorovoy from Gorovoy M.D. Eye Specialists has enrolled the first patient in the AMB-01-006 (NEXPEDE-1) study.

August 18, 2023
·
2 min read
Business

Medivir AB - Interim Report January - June 2023

Continued strong momentum and promising signs of patient benefit in the combination study with fostrox and Lenvima®.

August 18, 2023
·
5 min read
Can-Fite Submitted to FDA a Pediatric Plan to Allow Registration of Piclidenoson for the Treatment of Adolescents with Psoriasis

Can-Fite BioPharma Ltd today announced that it submitted a pediatric study plan to the U.S. Food and Drug Administration (FDA) for the treatment of adolescents suffering from psoriasis with Piclidenoson.

August 18, 2023
·
6 min read
BioCapital

Zalgen Immunotherapeutic Confers Complete Protection Against Advanced Multilineage Lassa Infections in Nonhuman Primates

Zalgen Labs LLC today announced publication of data demonstrating that Arevirumab-3®, its lead immunotherapeutic candidate, is an effective therapeutic for the treatment of Lassa virus infections, with activity against all major viral lineages that cause severe disease in humans, and at very low dosages.

August 18, 2023
·
4 min read